Pablo García Jaén: rFVIIa Shows Promise for Secondary Prophylaxis in Glanzmann Thrombasthenia
Pablo García Jaén, Specialist in Hematology and Hemotherapy at Salamanca University Healthcare Complex (CAUSA), shared on LinkedIn about a recent article he and his colleagues co-authored, published in RPTH, adding:
”Very pleased to share our recently published Brief Report in Research and Practice in Thrombosis and Haemostasis:
‘Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia’
In this multicenter Spanish study, we describe the use of rFVIIa as secondary prophylaxis in patients with Glanzmann thrombasthenia and recurrent severe bleeding despite standard therapy.
We are proud to contribute to the limited evidence in this rare inherited platelet disorder and to share the first Spanish Brief Report focused on this field.
Many thanks to all participating centers, colleagues, patients and families, as well as GEAPC, RETPLAC and SETH, for making this collaborative work possible.”
Title: Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia
Authors: Pablo García-Jaén, Nuria Fernández-Mosteirin, María Luisa Serrano, Susana Riesco, Carlos Aguilar, David Gabaldon, Sara Kanaan-Leis, Almudena González-Prieto, Raquel Portugal, María Carmen Mendoza, Carmen Gilabert, Ana Hortal, Lorena Díaz-Ajenjo, Ana Lama-Villanueva, Alba Mei González-Galán, Ana Sánchez-Fuentes, Rocío Benito, José Rivera, José Ramón González-Porras, José María Bastida

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice